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ABSTRACT 
Background:  The  composition  and  activities  of  indigenous  intestinal  microbiota  are  of 
paramount importance to human immunity, nutrition, and pathological processes, and hence, 
the health of the individual. It is well established that the intestine is an important site for 
local immunity. It is known that the effect of probiotics increases beneficial microbiota and 
improves chronic conditions such as atopic diseases, irritable bowel disease, and obesity. 
However, as there are so many probiotics, it is unknown which probiotics might have more of 
an impact upon intestinal microbiota.   
 
Objective: To understand how two different types of probiotics influence human intestinal 
microbiota, we analyzed human fecal microbiota after taking each of the probiotics. 
 
Methods: Five outpatients from Yoko Clinic (1 male and 4 females; aged between 34–46 
years  old)  were  enrolled  in  this  study.  None  of  the  subjects  had  cancer  or  any  active 
inflammatory diseases. The five patients took Lactobacillus buchneri (SU) for 4 weeks, no 
probiotics the following week, and mixed probiotics (NS) which are Lactobacillus plantarum 
(NS-5), Lactobacillus rhamnosus (NS-11), Lactobacillus delbruekii (NS-12), Lactobacillus 
helveticus (NS-8), Lactobacillus fermentum (NS-9) for the following 4 weeks. Fecal samples 
were collected before and after the outpatients took each of the two probiotics, and were then 
analyzed using a kit from Techno Suruga Laboratory Co., Ltd. The analysis of the microbiota 
was performed by targeting bacterial 16S rRNA genes with a terminal restriction fragment 
length polymorphism analysis program (Nagashima method). 
 
Results: Three patients of the five patients decreased the percentage of beneficial bacteria Functional Foods in Health and Disease 2013; 3(5):122-132                                                 Page 123 of 132 
(Lactobacillales, Bifidobacteria) after taking SU (13.7 ± 7.1% to 4.0 ± 3.5%), whereas the 
remaining two patients showed an increased percentage of beneficial bacteria (16.8 ± 3.4% to 
30.4 ± 4.6%). After taking NS, the three patients who decreased the percentage of beneficial 
bacteria  after  taking  SU  increased  their  beneficial  bacteria  (4.0  ±  3.5%  to  8.0  ±  2.1%), 
whereas  the  two  patients  who  increased  beneficial  bacteria  after  taking  SU  showed  a 
decreased percentage of beneficial bacteria (30.4 ± 4.6% to 16.4 ± 7.4%).   
 
Conclusion:  This  study  demonstrated  that  the  two  probiotics  had  different  influences. 
Probiotics should be selected not only for their quality but also for compatibility with each 
intestinal bacterial flora. 
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BACKGROUND: 
The bacterial count in the intestinal tract is more than 10
12 cells per gram of dry content [1-3], 
comprising approximately 40–500 species [4]. The composition and activities of indigenous 
intestinal microbiota are of paramount importance in human immunity, nutrition, pathological 
processes, and hence, the overall health of an individual [5]. The effect of probiotics increases 
the count of beneficial microbiota in the intestinal tract and improves chronic conditions, 
such as atopic diseases, irritable bowel disease, and obesity [6,7]. However, because there are 
several  probiotic  species,  it  is  remains  unknown  which  probiotics  may  have  more  of  an 
impact  upon  intestinal  microbiota.  To  understand  the  influence  of  two  different  types  of 
probiotics  on  human  intestinal  microbiota,  we  analyzed  human  fecal  microbiota  after 
supplementation of probiotics. 
 
INTRODUCTION: 
A  poor  diet   and   dysregulated  digestion  can  inhibit  nutrient  bioavailability  and 
absorption,  undermine  homeostasis,  and  can  create  conditions  favorable  for  the 
onset  of  disease  and  metabolic  disorders  [6,7].  The  benefits  of  balanced  intestinal 
microbiota include maintaining a strong digestive system, enhancing the bioavailability of 
nutrients  to  the  cells,  supporting  immune  function  and  cellular  viability,  and  removing 
metabolic byproducts and environmental toxins. 
Each individual has different intestinal microbiota which is depending on the exposure 
of the fetus to various microbes in the microbes in the birth canal, whether an infant is breast 
fed, daily diet, environmental and psychological stressors and the indiscriminating use of 
antibiotics. It has been reported that ethnicity can be a factor influencing different flora [4], 
and intestinal microbiota of the Japanese includes marine bacteria because of their diet [8]. In 
a  previous  experiment,  we  measured  the  human  intestinal  microbiota  among  different 
individuals and observed that each person contained different proportions of bacteria [9]. Functional Foods in Health and Disease 2013; 3(5):122-132                                                 Page 124 of 132 
Based  on  these  findings,  the  compatibility  of  probiotics  with  an  individual’s  intestinal 
microbiota content should be considered. 
 
MATERIALS AND METHODS:   
Population. All procedures in this study were performed in accordance with the guidelines of 
the 2000 Declaration of Helsinki for human experimentation, and all subjects provided signed 
informed consent.  Five outpatients (1 male and 4 females; age, 34–46 years)  from Yoko 
Clinic (Kitakyushu, Japan) were enrolled in this study. The patient characteristics are shown 
in Table 1. None of the subjects had cancer or active inflammatory diseases.   
 
Table 1 Clinical characteristics of the study subjects   
Patient        Age        Gender         Underlying disease 
No. 1          47        Male           Pollen allergy     
No. 2          41        Female         Asthma   
No. 3    56        Female         Atopic disease      
No. 4        41        Female         Constipation     
No. 5          34        Female         Chronic eruption        
 
Materials. In this study, we used two different kinds of probiotics: (1) The first probiotics 
(Origin Biochemical Inc.) is obtained from cultured rice used in Funa-zushi, which contains 
Lactopbacillus  buchneri  (SU),  and  is  consumed  as  a  traditional  health  food  in  Japan  to 
prevent the occurrence of colds and indigestion [10]. (2) The second (Laca Co.) probiotics is 
a  mixture  of  probiotics  (NS)  such  as  Lactobacillus  plantarum  (NS-5),  Lactobacillus 
rhamnosus (NS-11), Lactobacillus delbrueckii (NS-12), Lactobacillus helveticus (NS-8), and 
Lactobacillus fermentum (NS-9) which are cultured from a grass in Mongolia. 
 
Study Design. All five patients took SU for 4 weeks, no probiotics the following week, and 
NS for the next 4 weeks. Fecal samples were collected before and after supplementation of 
each of the two probiotics, and subsequently analyzed using an assay kit from Techno Suruga 
Laboratory Co., Ltd. No conditions were placed on the patients during this study in terms of 
dietary intake. 
 
Analysis of Fecal Microbiota. Fecal samples were collected three times (before probiotic 
supplementation, 4 weeks after SU administration, and 4 weeks after NS administration). 
Fecal  microbiota  was  analyzed  by  targeting  bacterial  16S  rRNA  genes  using  a  terminal 
restriction  fragment  length  polymorphism  (T-RFLP)  analysis  as  previously  described  by 
Nagashima et al. (11-13). The primers 516F (5′-TGCCAGCAGCCGCGGTA-3′) and 1510R 
(5′-GGTTACCTTGTTACGACTT-3′) were used to amplify the 16S rRNA genes. The 5′ ends 
of the 516F forward primer were labeled using 6′-carboxyfluorescein (6-FAM), which was 
synthesized by Applied Biosystems Japan (Tokyo, Japan). The purified PCR products (2 μL) Functional Foods in Health and Disease 2013; 3(5):122-132                                                 Page 125 of 132 
were digested with 10 U of BslI (New England BioLabs, Inc., Ipswich, USA) at 55°C for 3 h. 
The length of the terminal restriction fragments was determined using an ABI PRISM 3130xl 
genetic analyzer (Applied Biosystems, Tokyo, Japan). 
 
RESULTS: 
The percentage of beneficial bacteria decreased in three of the five patients (Lactobacillales, 
Bifidobacteria) after SU administration (13.7 ± 7.1% vs. 4.0 ± 3.5%), but increased in the 
remaining  two  patients  (16.8  ±  3.4%  vs.  30.4  ±  4.6%).  After  NS  administration,  the 
percentage of beneficial bacteria increased in the three patients who experienced a decrease 
in the percentage of beneficial bacteria after SU administration (4.0 ± 3.5% vs. 8.0 ± 2.1%), 
but decreased in the two patients who experienced an increase in beneficial bacteria after SU 
administration (30.4 ± 4.6% vs. 16.4 ± 7.4%) (Figure 1). 
 
Figure  1.  Beneficial  fecal  bacteria  (Lactobacillales  and  Bifidobacteria)  change  among 
prestudy and after taking Lactobacillus buchneri (SU), and mixed probiotics (NS).   
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According to Collins et al. [14], Clostridium clusters and subclusters cannot divide the 
unknown  that  is  beneficial  or  harmful  in  the  intestine.  For  example,  Faecalibacterium 
prausnitzii is an important butyrate-producing bacterium in Clostridium cluster IV. In contrast, 
Clostridium  perfringens  is  a  well-known  harmful  bacterium  in  Clostridium  cluster  I. 
Lactobacillales and Bifidobacteria are considered beneficial fecal bacteria. In this study, the 
beneficial bacterial count decreased in some patients. Clostridium showed no tendency after 
taking SU and NS either (data not shown). 
 
DISCUSSION: 
A healthy gastrointestinal tract  in individuals may not be properly established from birth 
because of some factors such as the environment inside the mother’s uterus and the through 
birth canal, a diet of breast milk and/or powdered milk, daily diet, as well as exposure to 
environmental toxins and stressors. Imbalances in intestinal microbiota may induce allergic 
diseases, metabolic syndrome, diabetes, obesity, immune disorders, and inflammatory bowel 
disease; however, supplementation of resident microbiota with probiotics may decrease the 
incidences of these diseases. For example, a recurrent Clostridium difficile infection can be 
treated by duodenal infusion of donor feces which means changing the recipient’s constituent 
microbiota content by decreasing the proportion of the Clostridium cluster IV and XIVa [15]. 
Probiotic supplementation is used worldwide to treat allergic diseases, skin disorders, and 
constipation.   
The  most  important  factors  for  improving  the  intestinal  microbiota  are  proper 
well-balanced  diet  and  minimal  exposure  to  environmental  and  psychological  stressors, 
although probiotic supplementation can also be beneficial. One report showed that the effect 
of a strict vegetarian diet on the intestinal microbiota was extremely different compared with 
that of non-vegetarian diet [16]. Probiotic supplementation may highlight the importance of 
intestinal care in everyday life. However, according to this study, the intestinal microbiota of 
some  patients  possibly  deteriorated  because  one  probiotic  was  incompatible.  Thus, 
consumption of incompatible probiotics may be harmful. As previously mentioned, because 
the intestinal microbiota is different in each person, compatibility of all probiotics should be 
considered. 
There were a few limitations to this study. First, the present study included a small 
study population, and second, the actual bacterial count was not determined by the method 
used.  T-RFLP  was  only  useful  for  estimating  the  bacterial  count.  Therefore,  a  more 
quantitative  method  for  bacterial  analysis  in  addition  to  the  analysis  of  cost  versus 
performance is required. 
In conclusion, this study demonstrated that the two types of probiotics had different 
effects;  therefore,  probiotics  should  be  selected  not  only  for  their  quality  but  also  for 
compatibility with the host’s intestinal microbiota.   
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